📊 VYGR Key Takeaways
Is Voyager Therapeutics, Inc. (VYGR) a Good Investment?
Voyager Therapeutics is a pre-commercial biotech company in severe financial distress with collapsing revenues (-49.5% YoY), massive operating losses (-$30.3M), and a burn rate of $33.4M annually that will exhaust the $43.3M cash position within approximately 15 months without revenue growth or capital raises. The fundamentals show deteriorating business momentum with no pathway to profitability visible in current financial trajectory.
Voyager Therapeutics, Inc. Key Strengths (VYGR)
- Strong balance sheet with $173.7M stockholders' equity and minimal debt
- Excellent liquidity position with 8.42x current ratio providing short-term financial stability
- Asset-light operations with minimal capex ($14K) reducing capital requirements
VYGR Stock Risks: Voyager Therapeutics, Inc. Investment Risks
- Severe revenue collapse of 49.5% YoY indicating failed commercialization or lost partnerships
- Unsustainable cash burn of $33.4M annually with only ~15 months of runway at current rate
- Massive operating losses (-$1,167% margin) with no profitability pathway or positive unit economics demonstrated
- High dilution risk requiring additional capital raises to continue operations
- Biotech execution risk with uncertain pipeline outcomes and no visible revenue recovery trajectory
Key Metrics to Watch
- Cash balance and monthly burn rate (critical survival metric with <18 month runway)
- Revenue trend stabilization and growth (currently in free fall)
- Operating cash flow management and path to cash flow breakeven
- Clinical pipeline advancement and partnership announcements (potential capital sources)
Voyager Therapeutics, Inc. (VYGR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.42x current ratio provides a solid financial cushion.
VYGR Profit Margin, ROE & Profitability Analysis
VYGR vs Healthcare Sector: How Voyager Therapeutics, Inc. Compares
How Voyager Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Voyager Therapeutics, Inc. Stock Overvalued? VYGR Valuation Analysis 2026
Based on fundamental analysis, Voyager Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Voyager Therapeutics, Inc. Balance Sheet: VYGR Debt, Cash & Liquidity
VYGR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Voyager Therapeutics, Inc.'s revenue has grown significantly by 46% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.97 reflects profitable operations.
VYGR Revenue Growth, EPS Growth & YoY Performance
VYGR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.6M | -$27.9M | $-0.47 |
| Q3 2025 | $13.4M | -$9.0M | $-0.16 |
| Q2 2025 | $5.2M | -$10.1M | $-0.18 |
| Q1 2025 | $6.5M | -$11.3M | $-0.20 |
| Q3 2024 | $4.6M | -$9.0M | $-0.16 |
| Q2 2024 | $4.9M | -$10.1M | $-0.18 |
| Q1 2024 | $19.5M | -$11.3M | $-0.20 |
| Q3 2023 | $4.6M | $17.6M | $0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Voyager Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VYGR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Voyager Therapeutics, Inc. (CIK: 0001640266)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VYGR
What is the AI rating for VYGR?
Voyager Therapeutics, Inc. (VYGR) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VYGR's key strengths?
Claude: Strong balance sheet with $173.7M stockholders' equity and minimal debt. Excellent liquidity position with 8.42x current ratio providing short-term financial stability.
What are the risks of investing in VYGR?
Claude: Severe revenue collapse of 49.5% YoY indicating failed commercialization or lost partnerships. Unsustainable cash burn of $33.4M annually with only ~15 months of runway at current rate.
What is VYGR's revenue and growth?
Voyager Therapeutics, Inc. reported revenue of $2.6M.
Does VYGR pay dividends?
Voyager Therapeutics, Inc. does not currently pay dividends.
Where can I find VYGR SEC filings?
Official SEC filings for Voyager Therapeutics, Inc. (CIK: 0001640266) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VYGR's EPS?
Voyager Therapeutics, Inc. has a diluted EPS of $-0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VYGR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Voyager Therapeutics, Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VYGR stock overvalued or undervalued?
Valuation metrics for VYGR: ROE of -16.1% (sector avg: 15%), net margin of -1,077.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VYGR's AI grade for 2026?
Our dual AI analysis gives Voyager Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VYGR's free cash flow?
Voyager Therapeutics, Inc.'s operating cash flow is $-33.4M, with capital expenditures of $14.0K. FCF margin is -1,289.4%.
How does VYGR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,077.4% (avg: 12%), ROE -16.1% (avg: 15%), current ratio 8.42 (avg: 2).